PSNL - Personalis, Inc. News

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS serv

This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targe

Aaron Tachibana Sells 2,931 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ: PSNL - Get Free Report) CFO Aaron Tachibana sold 2,931 shares of the stock

Stephen Michael Moore Sells 2,068 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ: PSNL - Get Free Report) SVP Stephen Moore sold 2,068 shares of the busines

Richard Chen Sells 3,998 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ: PSNL - Get Free Report) CMO Richard Chen sold 3,998 shares of the company'

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace

BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the follow

Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 7,459 Shares

Personalis, Inc. (NASDAQ: PSNL - Get Free Report) CEO Christopher Hall sold 7,459 shares of the firm

Reviewing Personalis (NASDAQ:PSNL) and Mettler-Toledo International (NYSE:MTD)

Mettler-Toledo International (NYSE: MTD - Get Free Report) and Personalis (NASDAQ: PSNL - Get Free R

gurufocus.com

Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?

Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 202

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis,

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the follow

Personalis, Inc. $PSNL Shares Bought by Bank of America Corp DE

Bank of America Corp DE lifted its position in shares of Personalis, Inc. (NASDAQ: PSNL) by 85.4% in

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages

Personalis, Inc. (NASDAQ: PSNL - Get Free Report) has been assigned an average rating of "Hold" from

What’s Going On With Tempus AI Stock on Monday?

Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA

On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans

On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Depa

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as

zacks.com

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estima

Personalis Q2 EPS $(0.30) Misses $(0.27) Estimate, Sales $22.357M Beat $16.783M Estimate

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.30) per share which missed the analyst con

businesswire.com

Personalis Reports Second Quarter Results and Recent Highlights

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for

PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis

MONSEY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is invest

prnewswire.com

Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Conta

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholde

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Sharehold

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LXP, DMAA, PSNL,

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &

prnewswire.com

Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Hold

BALA CYNWYD, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi

Benzinga Bulls and Bears: IBM, Super Micro, Tesla

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo

businesswire.com

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Prop

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de

Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks

Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holdin

Lake Street Downgrades Personalis to Hold, Announces $16.25 Price Target

Lake Street analyst Thomas Flaten downgrades Personalis (NASDAQ:PSNL) from Buy to Hold and announ

BTIG Maintains Buy on Personalis, Raises Price Target to $16.25

BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price targ

Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition

Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD

Tempus AI To Acquire Personalis In $1.5B Deal, Expanding Minimal Residual Disease Capabilities And P

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal dat

Needham Maintains Buy on Personalis, Raises Price Target to $17

Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price ta

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-

Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test

This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Re

Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $13

Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and ra

Personalis Wins EU Compliance Mark for Cancer Testing Blood Kits, Blood Collection Kits Receive Euro

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announce

Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types

Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clini

Personalis to Present New Cancer Detection Data at Major Oncology Conference

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announce

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients unde

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Morgan Stanley Maintains Equal-Weight on Personalis, Lowers Price Target to $9

Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and lo

BTIG Maintains Buy on Personalis, Lowers Price Target to $11

BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price targ

Personalis Affirms FY2026 Sales Guidance of $78.000M-$80.000M vs $78.758M Est

Personalis (NASDAQ:PSNL) affirms FY2026 sales outlook from $78.000 million-$80.000 million to $78.00

Personalis Q1 EPS $(0.29) Misses $(0.27) Estimate, Sales $15.472M Beat $14.483M Estimate

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.29) per share which missed the analyst con

Personalis Presents NeXT Personal ctDNA Data At AACR 2026 Showing 100% Sensitivity In Colorectal Can

Podium presentation on NeXT Personal monitoring neoadjuvant therapy in colorectal cancer;Real-world

Personalis Showcases New Cancer Test To Track Treatment Resistance In Real Time

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced toda